Odyssey Therapeutics

Odyssey Therapeutics, headquartered in Boston with additional locations in San Diego, Ann Arbor, and Frankfurt, is a biotechnology company recognized on the 2022 Endpoints 11 list by Endpoints News for its promising potential. The company focuses on pioneering next-generation precision immunomodulators and oncology medicines, targeting high clinical and commercial potential areas, including those previously considered ‘undruggable.’ Odyssey employs a highly integrated drug hunting engine that merges established and newly-emerging drug discovery technologies, including CRISPR-based functional genomic screening, CRISPR-Cas9 base-editing, and advanced cell culture and in vivo models of tumor biology. Their comprehensive drug discovery and development platform combines computational and experimental technologies, utilizing AI, ML, and computational chemistry in collaboration with Janssen Pharmaceutica NV. Since its founding in late 2021, Odyssey has raised $487 million in capital, including a $101 million Series C financing round in December 2023. The company is rapidly advancing multiple pre-clinical programs in immunology and oncology, and presented data for three immunology programs at the American College of Rheumatology Convergence 2023 meeting. As a member of the Cancer Dependency Map (DepMap) 2.0 consortium sponsored by the BROAD institute, Odyssey is developing a portfolio of medicines designed to go beyond current treatment boundaries, focusing on inflammatory diseases and cancer. Their proprietary small molecule libraries and in silico discovery platform enhance their hit finding and target-centric screening capabilities, aiming to optimize small molecule medicines through multiparameter-based lead optimization.